Back to top

Piper Sandler Remains a Buy on Lexicon Pharmaceuticals (LXRX)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Lexicon Pharmaceuticals today and set a price target of $6.00. Rahimi covers the He...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Lexicon Pharmaceuticals, Inc. (LXRX)